Eli Lilly acquired Verve Therapeutics for over $1 billion upfront to bolster its strategic presence in the genetic medicine and cardiovascular disease treatment sectors. The acquisition brought Verve's pioneering in vivo gene-editing pipeline—specifically its single-course treatments designed to target disease-driving genes like PCSK9—directly into Lilly's internal research portfolio. By integrating Verve's cutting-edge scientific platform, Lilly aims to leverage its massive global clinical development and commercial infrastructure to transform chronic cardiovascular care into permanent, one-time preventative gene therapies.